
Mona Aslani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1673688/publications.pdf Version: 2024-02-01



MONA ASLANI

#	Article	IF	CITATIONS
1	Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients. Iranian Journal of Allergy, Asthma and Immunology, 2022, 21, 44-54.	0.4	2
2	Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. International Immunopharmacology, 2022, 110, 109040.	3.8	4
3	Influence of Î ² -D-mannuronic Acid, as a New Member of Non-steroidal Anti- Inflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis. Current Drug Discovery Technologies, 2021, 18, 65-74.	1.2	5
4	Efficient roles of miR-146a in cellular and molecular mechanisms of neuroinflammatory disorders: An effectual review in neuroimmunology. Immunology Letters, 2021, 238, 1-20.	2.5	13
5	Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs. International Immunopharmacology, 2021, 101, 108172.	3.8	19
6	Immunopharmacological effect of βâ€≺scp>dâ€mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miRâ€155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients. Drug Development Research, 2020, 81, 295-304.	2.9	14
7	The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery, 2020, 14, 69-77.	3.6	5
8	A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases. Immunology Letters, 2020, 227, 8-27.	2.5	32
9	The role of β- <scp>d</scp> -mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients. Immunopharmacology and Immunotoxicology, 2020, 42, 228-236.	2.4	7
10	Mannuronic Acid in Lowâ€Risk and Intermediateâ€1â€Risk Myelodysplastic Syndromes. Journal of Clinical Pharmacology, 2020, 60, 879-888.	2.0	0
11	The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients. Current Drug Discovery Technologies, 2020, 17, 704-710.	1.2	1
12	International multicenter randomized, placebo-controlled phase III clinical trial of β-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology, 2019, 27, 911-921.	3.9	13